Veru (NASDAQ:VERU – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.
Risk & Volatility
Veru has a beta of -1.2, meaning that its stock price is 220% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Veru and BeOne Medicines, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veru | 1 | 0 | 3 | 0 | 2.50 |
| BeOne Medicines | 0 | 1 | 16 | 1 | 3.00 |
Veru presently has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. BeOne Medicines has a consensus target price of $436.92, suggesting a potential upside of 5.04%. Given Veru’s higher probable upside, equities research analysts plainly believe Veru is more favorable than BeOne Medicines.
Earnings and Valuation
This table compares Veru and BeOne Medicines”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veru | N/A | N/A | -$22.73 million | ($0.69) | -3.07 |
| BeOne Medicines | $6.61 billion | 6.91 | $286.93 million | $7.87 | 52.85 |
BeOne Medicines has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
47.2% of Veru shares are owned by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Veru and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veru | N/A | -47.58% | -35.83% |
| BeOne Medicines | 13.86% | 19.04% | 10.70% |
Summary
BeOne Medicines beats Veru on 12 of the 14 factors compared between the two stocks.
About Veru
Veru Inc. is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function. Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.
About BeOne Medicines
BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
